tiprankstipranks
Trending News
More News >
Propanc Biopharma (PPCB)
NASDAQ:PPCB
US Market

Propanc Biopharma (PPCB) Price & Analysis

Compare
63 Followers

PPCB Stock Chart & Stats

$0.19
$0.00(0.00%)
At close: 4:00 PM EST
$0.19
$0.00(0.00%)

Propanc Biopharma News

PPCB FAQ

What was Propanc Biopharma’s price range in the past 12 months?
Propanc Biopharma lowest stock price was $0.15 and its highest was $11.00 in the past 12 months.
    What is Propanc Biopharma’s market cap?
    Propanc Biopharma’s market cap is $2.70M.
      When is Propanc Biopharma’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Propanc Biopharma’s earnings last quarter?
      Currently, no data Available
      Is Propanc Biopharma overvalued?
      According to Wall Street analysts Propanc Biopharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Propanc Biopharma pay dividends?
        Propanc Biopharma does not currently pay dividends.
        What is Propanc Biopharma’s EPS estimate?
        Propanc Biopharma’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Propanc Biopharma have?
        Propanc Biopharma has 13,364,244 shares outstanding.
          What happened to Propanc Biopharma’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Propanc Biopharma?
          Currently, no hedge funds are holding shares in PPCB
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Company Description

            Propanc Biopharma

            Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
            Similar Stocks
            Company
            Price & Change
            Follow
            Verrica Pharmaceuticals
            Barinthus Biotherapeutics
            Telomir Pharmaceuticals, Inc.
            Popular Stocks